Nartograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) biologic that stimulates the bone marrow to produce neutrophils, playing a critical role in treating congenital neutropenia,… Read more
Nartograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) biologic that stimulates the bone marrow to produce neutrophils, playing a critical role in treating congenital neutropenia, idiopathic neutropenia, and neutropenia associated with chemotherapy or bone marrow transplants. To support the rigorous analytical demands of pharmaceutical development, this category provides high-quality reference standards essential for comprehensive quality control and method validation. Laboratories rely on these materials, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds, for accurate impurity profiling and precise quantitation during stability testing and release assays. By utilizing these well-characterized reference materials, scientists can effectively monitor product consistency, ensure compliance with regulatory standards, and maintain the safety and efficacy of Nartograstim throughout its lifecycle.